Phio Pharmaceuticals (PHIO) Enterprise Value (2012 - 2026)

Phio Pharmaceuticals (PHIO) has reported Enterprise Value for 15 consecutive years, with -$1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 328.98% year-over-year to -$1.1 million; the trailing twelve-month figure through Jun 2026 stood at -$1.1 million (down 328.98% YoY), and the FY2025 full-year result was -$14.7 million, down 271.99% from the prior year.
• Enterprise Value rose to -$1.1 million in Q2 2026 per PHIO's latest filing, from -$2.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at $3.6 million in Q3 2025 and bottomed at -$14.7 million in Q4 2025.
• Historically, Enterprise Value has averaged -$4.6 million across 5 years, with a median of -$4.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value tumbled 826.14% in 2022, then soared 274.71% in 2025.
• Over 5 years, Enterprise Value stood at -$6.7 million in 2022, then retreated by 3.14% to -$6.9 million in 2023, then jumped by 42.6% to -$4.0 million in 2024, then sank by 271.99% to -$14.7 million in 2025, then surged by 92.23% to -$1.1 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$1.1 million, -$2.9 million, and -$14.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.